Literature DB >> 8098030

Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

W M Glazer1, H Morgenstern, J T Doucette.   

Abstract

BACKGROUND: Tardive dyskinesia (TD) has been a source of great concern to the psychiatric community because of the iatrogenic nature of the illness. Little is known about the risk of developing TD if neuroleptic medications are continued.
METHOD: This paper presents long-term risk estimates for TD in a prospective cohort study of 362 chronic psychiatric outpatients who were free of TD at baseline and who were maintained on neuroleptic medications.
RESULTS: On the basis of 5 years of follow-up, we estimate the risk of persistent TD to be 32% after 5 years of neuroleptic exposure (95% confidence interval [CI] = 23%-43%), 57% after 15 years of exposure (95% CI = 47%-66%), and 68% after 25 years of exposure (95% CI = 58%-77%). For patients with 10 years of previous neuroleptic exposure, the risk is 15% after 5 more years of exposure (95% CI = 7.2%-27%) and 38% after 15 more years of exposure (95% CI = 24%-53%). Our results fall within the wide range of results found in other studies of TD incidence. Differences in incidence across studies may be explained in terms of patient characteristics and other methodological factors.
CONCLUSION: One implication of this finding is that patients in the first 5 years of exposure could be targeted for prevention programs if resources are limited. A potential methodological problem encountered when studying chronically exposed patients is that they may have acquired TD (persistent) prior to the study and remitted before entry.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098030

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  28 in total

1.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Extrapyramidal side-effects of antipsychotics in a randomised trial.

Authors:  Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-10       Impact factor: 9.319

Review 4.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

5.  Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.

Authors:  Mara Balda; Maria Calvó; Eduardo Padilla; Gonzalo Guerrero; Juan Molina; Nestor V Florenzano; Danielle Kamis; Javier I Escobar; C Robert Cloninger; Gabriel de Erausquin
Journal:  Focus (Am Psychiatr Publ)       Date:  2015

6.  BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

Authors:  Itaru Miura; Jian-Ping Zhang; Masahiro Nitta; Todd Lencz; John M Kane; Anil K Malhotra; Hirooki Yabe; Christoph U Correll
Journal:  Schizophr Res       Date:  2014-01-07       Impact factor: 4.939

7.  Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Authors:  Stanley N Caroff; Vicki G Davis; Del D Miller; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; E Cabrina Campbell; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

8.  Major complications of neuroleptic drug use.

Authors:  A J Gelenberg
Journal:  West J Med       Date:  1994-01

9.  Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study.

Authors:  Julio Bobes; J Rejas; M Garcia-Garcia; F Rico-Villademoros; M P García-Portilla; M Madrigal; G Hernández
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

Review 10.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.